Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials.
about
Global Aesthetics Consensus: Hyaluronic Acid Fillers and Botulinum Toxin Type A-Recommendations for Combined Treatment and Optimizing Outcomes in Diverse Patient Populations.Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?Complications associated with cutaneous aesthetic procedures.Effect of baseline spastic hemiparesis on recovery of upper-limb function following botulinum toxin type A injections and postinjection therapyRemoval of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics.Neutralizing antibodies to botulinum neurotoxin type A in aesthetic medicine: five case reports.Medium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder.Immunogenicity of botulinum toxins.Chronic migraine - new treatment options.Therapeutic use of botulinum toxin in neurorehabilitation.Benefits and Risks of Non-Approved Injection Regimens for Botulinum Toxins in Spasticity.Efficacy of Cerebrolysin in the reduction of spasticity during stroke rehabilitation.Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products.Multichannel Electromyographic Mapping to Optimize OnabotulinumtoxinA Efficacy in Cervical Dystonia.Antibodies after botulinum toxin A injection into musculus detrusor vesicae: incidence and clinical relevance.Botulinum Toxin in Management of Limb Tremor.
P2860
Q30835378-43348F86-28D5-4A45-9B2E-5080841C258FQ34443530-7E37541A-B763-4D6E-8763-AC3C6557731FQ35692409-352AEA29-3365-45B8-BD48-A8D32543777DQ35795194-D3BE298C-C521-4876-A625-02754B37FA70Q37376557-0DC3A7C9-8871-4293-A6A3-09C6BAC3BFBDQ37412495-320EEA8F-29FA-4BF7-AE95-FC4687683219Q37514596-1BD5415A-0DFE-41E7-A173-87394A4DCAC1Q38046142-5F5E9D32-8817-46EE-9820-1899A55AABD0Q38364187-F2C75829-F71A-470B-B56F-BCE5E9428857Q38414925-A4134053-51CB-4711-93EC-CCDC618F5119Q39446871-C0122160-3A82-43E9-B3BD-24EC55FFD571Q42650695-87E834E9-46AA-45AC-8B7B-D6B6B642FFD7Q43185582-3416AEE0-3340-4F81-B097-268C0F4AB1CAQ43243497-743F181D-C2F4-497F-928D-89566C67C708Q44430026-17BB9464-C29E-4804-A8CA-41DF19A60283Q47142078-C5388AE2-83A7-41BB-B528-E030C759A459
P2860
Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials.
description
2007 nî lūn-bûn
@nan
2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Formation of neutralizing anti ...... ysis of three clinical trials.
@ast
Formation of neutralizing anti ...... ysis of three clinical trials.
@en
type
label
Formation of neutralizing anti ...... ysis of three clinical trials.
@ast
Formation of neutralizing anti ...... ysis of three clinical trials.
@en
prefLabel
Formation of neutralizing anti ...... ysis of three clinical trials.
@ast
Formation of neutralizing anti ...... ysis of three clinical trials.
@en
P2093
P1476
Formation of neutralizing anti ...... ysis of three clinical trials.
@en
P2093
Allison Brashear
Catherine C Turkel
Elie P Elovic
Jingyu Liu
Mark F Gordon
Mitchell F Brin
Simon Daggett
Stuart A Yablon
P304
P356
10.1016/J.CLINTHERA.2007.04.015
P577
2007-04-01T00:00:00Z